Basit öğe kaydını göster

dc.contributor.authorTanakol, Refik
dc.contributor.authorBilgic, Bilge
dc.contributor.authorSelcukbiricik, Özlem
dc.contributor.authorUzum, Ayse Kubat
dc.contributor.authorAral, Ferihan
dc.contributor.authorHacisahinogullari, Hulya
dc.contributor.authorYalin, Gulsah Yenidunya
dc.contributor.authorGul, Nurdan
dc.date.accessioned2023-02-21T10:23:31Z
dc.date.available2023-02-21T10:23:31Z
dc.date.issued2022
dc.identifier.citationHacisahinogullari H., Yalin G. Y., Selcukbiricik Ö., Gul N., Bilgic B., Uzum A. K., Tanakol R., Aral F., "Effect of Cabergoline Treatment on Disease Control in Acromegaly Patients.", Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, cilt.54, sa.10, ss.664-670, 2022
dc.identifier.issn0018-5043
dc.identifier.othervv_1032021
dc.identifier.otherav_42e4f839-2cdf-4aa3-8259-9a055c95516b
dc.identifier.urihttp://hdl.handle.net/20.500.12627/188360
dc.identifier.urihttps://doi.org/10.1055/a-1930-6585
dc.description.abstractThe aim of this study was to evaluate the efficacy of cabergoline in normalizing plasma IGF-I levels in acromegaly patients with elevated IGF-I levels after surgery and/or SRL therapy. Acromegaly patients (n: 143) were evaluated retrospectively. Patients with elevated IGF-I levels after surgery and/or SRLs therapy and a fixed dose of SRLs treatment for the last six months with no history of radiotherapy in the last three years were included in the study (n: 12). Previous treatment regimens, baseline PRL and IGF-I levels (ULNR), sella MRI, and immunohistochemical findings were evaluated. Cabergoline was used as an add on (n: 11) or single medical treatment (n: 1). The median duration of treatment with SRL alone was 12 months (range 6-48 months). The mean IGF-I value before cabergoline therapy was 1.45 +/- 0.4 ULNR. The mean cabergoline dose and duration of treatment were 1.55 +/- 0.75 mg/week and 9 +/- 6.3 months, respectively. IGF-I normalization was only achieved in patients with serum IGF-I concentration<1.5xULNR before the onset of cabergoline treatment (n: 9). In some of the patients with IGF-I normalization, baseline prolactin levels were normal (n: 3). Immunopositivity for prolactin in adenoma tissue was found in three patients with IGF-I normalization. Cabergoline therapy is effective in the normalization of IGF-I levels even in normoprolactinemic acromegaly patients when IGF-I levels are mildly or moderately elevated during SRL therapy.
dc.language.isoeng
dc.subjectEndokrin ve Otonom Sistemler
dc.subjectEndokrinoloji, Diyabet ve Metabolizma
dc.subjectEndokrinoloji
dc.subjectYaşam Bilimleri
dc.subjectİç Hastalıkları
dc.subjectEndokrinoloji ve Metabolizma Hastalıkları
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectENDOKRİNOLOJİ VE METABOLİZMA
dc.titleEffect of Cabergoline Treatment on Disease Control in Acromegaly Patients.
dc.typeMakale
dc.relation.journalHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume54
dc.identifier.issue10
dc.identifier.startpage664
dc.identifier.endpage670
dc.contributor.firstauthorID4065461


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster